Analysis of glucagon-like peptide-1 receptor agonists reveals a complex relationship with hair loss, particularly telogen effluvium and androgenic alopecia. Risk appears highest with tirzepatide and semaglutide at higher doses and longer treatment duration, potentially linked to rapid weight loss exceeding normal physiological adaptation rates. The mechanisms likely involve disrupted hair follicle cycling through metabolic stress, altered dermal fat tissue that supports follicular function, and hormonal fluctuations affecting growth phases. However, the same medications paradoxically improved inflammatory alopecia in metabolically compromised patients, suggesting the underlying health status determines hair outcomes. This contradiction highlights the intricate relationship between metabolic health and hair biology that current research barely understands. For the millions now using these medications, this represents a significant blind spot requiring urgent attention. The finding challenges the assumption that weight loss universally benefits health outcomes and suggests dermatologists must now screen GLP-1 users proactively. Given these drugs' explosive popularity and long-term use patterns, establishing clear risk profiles and mitigation strategies becomes critical for informed patient counseling.